Latest Breaking News On - காலை துணிகர - Page 1 : comparemela.com
Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Stealth BioTherapeutics Reports Second Quarter 2021 Financial Results And Recent Business Highlights
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Abbisko and Sperogenix Announce An Exclusive Agreement to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China
July 5, 2021 GMT
SHANGHAI, BEIJING, HONG KONG, July 4, 2021 /PRNewswire/ Sperogenix (Shanghai) MedTech Co., Ltd. (“Sperogenix”), a subsidiary of Sperogenix Therapeutics (platform company for development and commercialization of rare diseases medications in China), has entered into an exclusive licensing agreement with Abbisko Therapeutics Co., Ltd. (“Abbisko”), a Chinese biopharmaceutical company focused on innovative drug discovery and development, to collaborate on the development and commercialization of innovative drug ABSK021 for indications in the field of rare neurological diseases.
Stealth BioTherapeutics Reports Fiscal Year 2020 Financial Results And Recent Business Highlights
Phase 2b dry AMD patient recruitment completed with topline data expected Q2 2022
NDA submission for elamipretide for cardiomyopathy in Barth syndrome may be delayed based on recent FDA feedback and ongoing interactions
Clinical expansion efforts underway for elamipretide in rare metabolic cardiomyopathies and in rare mitochondrial disease caused by nuclear DNA mutations
Pipeline development ongoing with SBT-272, SBT-550, and other pipeline compounds
Management to host conference call today at 8:30am ET
News provided by
Share this article
Share this article
BOSTON, April 6, 2021 /PRNewswire/ Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today reported financial results for the year ended December 31, 2020 and a
China Digest: Muliang eyes $40m Nasdaq IPO; neoX Biotech, Resproly raise fresh capital
Source: Markus Winkler/Unsplash
February 2, 2021
Chinese fertiliser producer Muliang is seeking to raise $40 million in a Nasdaq IPO, while biotech startup neoX Biotech and inhalation therapy developer Resproly have closed new funding rounds to expand operations.
Fertiliser producer Muliang to raise $40m in Nasdaq IPO
Chinese fertiliser producer Muliang Viagoo Technology (MLVG) is seeking to raise $40 million on the Nasdaq this week by offering 10 million shares at a price of $4 apiece. At the proposed deal size, Muliang would command a market cap of $194 million.
Formed in 2014 under the laws of the state of Nevada, US, Muliang conducts business primarily through Shanghai Muliang, a variable interest entity (VIE) created under the laws of China, to engage in the manufacturing and distribution of organic fertilisers and the sales of agricultural products in China. Its organic fertiliser produ
vimarsana © 2020. All Rights Reserved.